Orthocell Ltd (AU:OCC) has released an update.
Orthocell Ltd’s Striate+ dental membrane has achieved a remarkable 98.6% success rate in a post-market clinical study, confirming its efficacy in guided bone regeneration and dental implant procedures. The study’s results, set to be presented at the European Association for Osseintegration, highlight Striate+’s potential to enhance Orthocell’s market presence in a sector estimated to be worth over $700 million annually. This success bolsters the product’s standing among dental professionals and Orthocell’s distribution partner, BioHorizons, is expected to see increased product adoption.
For further insights into AU:OCC stock, check out TipRanks’ Stock Analysis page.
